Last reviewed · How we verify

NCT03484702: TRANSCENDWORLD

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

Completed Phase 2 Results posted Last updated 27 December 2024
What this trial tests

Phase 2 trial testing JCAR017 in Lymphoma, Non-Hodgkin in 113 participants. Completed in 15 December 2023.

Timeline
5 June 2018
Primary endpoint
15 December 2023
15 December 2023

Quick facts

Lead sponsorCelgene
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment113
Start date5 June 2018
Primary completion15 December 2023
Estimated completion15 December 2023
Sites20 locations across France, Italy, Finland, Japan, Netherlands, Belgium, Austria, United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Lymphoma, Non-Hodgkin. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Overall Response Rate (ORR) Per Independent Review Committee in Cohorts 1, 2 and 3 Primary · From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)

Overall response rate (ORR) by Independent Review Committee (Cohorts 1, 2, 3). ORR is the percent of participants with best overall response of complete response (CR) or partial response (PR). Complete response via PET-CT: * Lymph nodes/extralymphatic: Score 1, 2, 3a with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Complete response via CT scan: * Lymph nodes/extralymphatic: Target nodes/nodal masses ≤ 1.5 cm longest transverse diameter. * Nonmeasured lesion: No * New lesions: No * Bone marrow: Normal Partial response via PET-CT: * Lymph no

GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy61.143.5 – 76.9
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy63.042.4 – 80.6
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 270.034.8 – 93.3
Overall Response Rate (ORR) Per Investigator in Cohort 4 Primary · From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)

Overall response rate (ORR) is the percent of participants with best overall response of complete response (CR) or partial response (PR). Complete response via PET-CT: * Lymph nodes/extralymphatic: Score 1, 2, 3a with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Complete response via CT scan: * Lymph nodes/extralymphatic: Target nodes/nodal masses ≤ 1.5 cm longest transverse diameter. * Nonmeasured lesion: None * New lesions: No * Bone marrow: Normal Partial response via PET-CT: * Lymph nodes/extralymphatic: Score 4, 5b, reduced uptake from

GroupValue95% CI
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma100100 – 100
Overall Response Rate (ORR) Per Investigator in Cohort 5 Primary · From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)

Overall response rate (ORR) determined by Investigator assessment after JCAR017 infusion. The ORR is the percent of participants with best overall response (BOR) of either complete response (CR), complete response unconfirmed (Cru) or partial response (PR). Complete response (CR): * Brain imaging: No contrast enhancement * Corticosteroid dose: None * Eye examination: Normal * Cerebrospinal fluid cytology: Negative Complete response unconfirmed (CRu): * Brain imaging: No contrast enhancement, Minimal abnormality * Corticosteroid dose: Any * Eye examination: Normal, minor RPE abnormality * C

GroupValue95% CI
Cohort 5: Primary Central Nervous System Lymphoma80.028.4 – 99.5
Number of Participants With Adverse Events in Cohort 7 Primary · From leukapheresis to end of study (up to approximately 63 months)

An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. Graded according to NCI CTCAE (Version 4.03) guidelines where grade 1 = mild, grade 2 = moderate,

AEs occurring between leukapheresis and lymphodepleting chemotherapy (LDC)
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting0
AEs occurring between LDC and JCAR017 infusion
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting2
AEs occurring between JCAR017 infusion and Day 30
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting9
AEs occurring between Day 31 and Day 90
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting7
AEs occurring between Day 91 and end of study
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting7
Number of Participants With Serious Adverse Events (SAEs) in Cohort 7 Primary · From leukapheresis to end of study (up to approximately 63 months)

A serious adverse event (SAE) is defined as any adverse event (AE) occurring at any dose that: * Results in death; * Is life-threatening (ie, in the opinion of the Investigator, the participant is at immediate risk of death from the AE); * Requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay). * Results in persistent or significant disability/incapacity (a substantial disruption of the participant's ability to conduct normal life functions); * Is a congenital anomaly/birth defect; * C

SAEs occurring between leukapheresis and lymphodepleting chemotherapy (LDC)
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting0
SAEs occurring between LDC and JCAR017 infusion
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting0
SAEs occurring between JCAR017 infusion and Day 30
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting1
SAEs occurring between Day 31 and Day 90
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting0
SAEs occurring between Day 91 and end of study
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting1
Number of Participants With Increase From Baseline in Select Hematology Parameters - Cohort 7 Primary · At Baseline and Day 29 after JCAR017 infusion

JCAR017 treatment-emergent laboratory abnormalities are defined as an abnormality that, compared to baseline, worsens by at least one grade after JCAR017 infusion. The baseline value is defined as the last available recorded value on or prior to the date of JCAR017 infusion. Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life-threatening), Grade 5 (Death).

Leukocytes (10^9/L) - Day 29
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting0
Neutrophils, Segmented (10^9/L) - Day 29
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting2
Platelets (10^9/L) - Day 29
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting5
Activated Partial Thromboplastin Time (sec) - Day 29
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting0
Prothrombin Intl. Normalized Ratio - Day 29
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting1
Number of Participants With Increase From Baseline in Select Serum Chemistry Parameters - Cohort 7 Primary · At Baseline and Day 29 after JCAR017 infusion

JCAR017 treatment-emergent laboratory abnormalities are defined as an abnormality that, compared to baseline, worsens by at least one grade after JCAR017 infusion. The baseline value is defined as the last available recorded value on or prior to the date of JCAR017 infusion. Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life-threatening), Grade 5 (Death).

Albumin (g/L) - Day 29
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting0
Phosphate (mmol/L) - Day 29
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting0
Alkaline Phosphatase (U/L) - Day 29
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting0
Alanine Aminotransferase (U/L) - Day 29
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting0
Aspartate Aminotransferase (U/L) - Day 29
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting1
Bilirubin (umol/L) - Day 29
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting0
Creatinine (umol/L) - Day 29
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting7
Triglycerides (mmol/L) - Day 29
GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting3
Number of Participants With Adverse Events in Cohorts 1, 2, 3, 4, and 5 Secondary · From leukapheresis to end of study (up to approximately 63 months)

An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. Graded according to NCI CTCAE (Version 4.03) guidelines where grade 1 = mild, grade 2 = moderate,

AEs occurring between leukapheresis and lymphodepleting chemotherapy (LDC)
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy5
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy5
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 20
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma0
AEs occurring between LDC and JCAR017 infusion
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy29
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy23
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 28
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma4
AEs occurring between JCAR017 infusion and Day 30
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy36
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy26
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 210
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma1
Cohort 5: Primary Central Nervous System Lymphoma5
AEs occurring between Day 31 and Day 90
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy25
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy10
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 28
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma1
Cohort 5: Primary Central Nervous System Lymphoma3
AEs occurring between Day 91 and end of study
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy10
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy9
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 27
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma2
Number of Participants With Serious Adverse Events (SAEs) in Cohorts 1, 2, 3, 4, and 5 Secondary · From leukapheresis to end of study (up to approximately 63 months)

A serious adverse event (SAE) is defined as any adverse event (AE) occurring at any dose that: * Results in death; * Is life-threatening (ie, in the opinion of the Investigator, the participant is at immediate risk of death from the AE); * Requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay). * Results in persistent or significant disability/incapacity (a substantial disruption of the participant's ability to conduct normal life functions); * Is a congenital anomaly/birth defect; * C

SAEs occurring between leukapheresis and lymphodepleting chemotherapy (LDC)
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy0
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy1
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 20
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma0
SAEs occurring between LDC and JCAR017 infusion
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy1
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy0
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 20
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma0
SAEs occurring between JCAR017 infusion and Day 30
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy16
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy7
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 20
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma1
SAEs occurring between Day 31 and Day 90
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy7
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy3
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 22
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma1
SAEs occurring between Day 91 and end of study
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy5
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy3
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 21
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma0
Number of Participants With Increase From Baseline in Select Hematology Parameters - Cohorts 1, 2, 3, 4, and 5 Secondary · At Baseline and Day 29 after JCAR017 infusion

JCAR017 treatment-emergent laboratory abnormalities are defined as an abnormality that, compared to baseline, worsens by at least one grade after JCAR017 infusion. The baseline value is defined as the last available recorded value on or prior to the date of JCAR017 infusion. Grade 1 = Mild, Grade 2 =Moderate, Grade 3 =Severe, Grade 4 =Life-threatening, Grade 5 =Death.

Leukocytes (10^9/L) - Day 29
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy4
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy2
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 21
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma1
Neutrophils, Segmented (10^9/L) - Day 29
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy11
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy6
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 23
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma1
Platelets (10^9/L) - Day 29
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy13
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy8
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 29
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma1
Cohort 5: Primary Central Nervous System Lymphoma3
Activated Partial Thromboplastin Time (sec) - Day 29
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy0
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy1
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 21
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma1
Prothrombin Intl. Normalized Ratio - Day 29
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy1
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy0
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 20
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma0
Number of Participants With Increase From Baseline in Select Serum Chemistry Parameters - Cohorts 1, 2, 3, 4, and 5 Secondary · At Baseline and Day 29 after JCAR017 infusion

JCAR017 treatment-emergent laboratory abnormalities are defined as an abnormality that, compared to baseline, worsens by at least one grade after JCAR017 infusion. The baseline value is defined as the last available recorded value on or prior to the date of JCAR017 infusion. Grade 1 = Mild, Grade 2 =Moderate, Grade 3 =Severe, Grade 4 =Life-threatening, Grade 5 =Death.

Albumin (g/L) - Day 29
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy0
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy0
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 20
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma0
Phosphate (mmol/L) - Day 29
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy0
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy1
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 20
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma0
Alkaline Phosphatase (U/L) - Day 29
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy2
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy1
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 20
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma1
Alanine Aminotransferase (U/L) - Day 29
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy10
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy3
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 21
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma2
Aspartate Aminotransferase (U/L) - Day 29
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy6
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy3
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 21
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma3
Bilirubin (umol/L) - Day 29
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy2
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy0
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 20
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma0
Creatinine (umol/L) - Day 29
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy23
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy20
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 26
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma1
Cohort 5: Primary Central Nervous System Lymphoma3
Triglycerides (mmol/L) - Day 29
GroupValue95% CI
Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy10
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy6
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 22
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma0
Cohort 5: Primary Central Nervous System Lymphoma2
Overall Response Rate (ORR) in Cohort 7 Secondary · From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)

ORR by Independent Review Committee. ORR is the percent of participants with best overall response of complete response (CR) or partial response (PR). Complete response via PET-CT: * Lymph nodes/extralymphatic: Score 1, 2, 3a with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Complete response via CT scan: * Lymph nodes/extralymphatic: Target nodes/nodal masses ≤ 1.5 cm longest transverse diameter. * Nonmeasured lesion: None * New lesions: No * Bone marrow: Normal Partial response via PET-CT: * Lymph nodes/extralymphatic: Score 4, 5b, reduced

GroupValue95% CI
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting88.951.8 – 99.7

Adverse events — posted to ClinicalTrials.gov

Time frame: Participants were assessed for All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events from their date of leukapheresis until their study completion (assessed up to approximately 63 months).. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy
Serious: 19/45 (42%)
Deaths: 32/45
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy
Serious: 8/32 (25%)
Deaths: 22/32
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2
Serious: 2/14 (14%)
Deaths: 9/14
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma
Serious: 0/4 (0%)
Deaths: 0/4
Cohort 5: Primary Central Nervous System Lymphoma
Serious: 2/7 (29%)
Deaths: 5/7
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting
Serious: 1/11 (9%)
Deaths: 4/11

Serious adverse events (52 terms)

ReactionSystemCohort 1: Diffuse B-cell L…Cohort 2: Transplant Ineli…Cohort 3: Japan Specific -…Cohort 4: Newly Diagnosed …Cohort 5: Primary Central …Cohort 7: Meeting Cohort 1…
Cytokine release syndromeImmune system disorders
TremorNervous system disorders
Confusional statePsychiatric disorders
Febrile neutropeniaBlood and lymphatic system disorders
AphasiaNervous system disorders
Abdominal painGastrointestinal disorders
Haemophagocytic lymphohistiocytosisImmune system disorders
Candida sepsisInfections and infestations
Memory impairmentNervous system disorders
SomnolenceNervous system disorders
DeliriumPsychiatric disorders
DisorientationPsychiatric disorders
AnaemiaBlood and lymphatic system disorders
NeutropeniaBlood and lymphatic system disorders
ThrombocytopeniaBlood and lymphatic system disorders
Cardiac failureCardiac disorders
Hypercalcaemia of malignancyEndocrine disorders
Ulcerative keratitisEye disorders
AscitesGastrointestinal disorders
ConstipationGastrointestinal disorders
Gastric haemorrhageGastrointestinal disorders
MelaenaGastrointestinal disorders
Multiple organ dysfunction syndromeGeneral disorders
PyrexiaGeneral disorders
HypertransaminasaemiaHepatobiliary disorders
Other adverse events (59 terms — click to expand)

ReactionSystemCohort 1: Diffuse B-cell L…Cohort 2: Transplant Ineli…Cohort 3: Japan Specific -…Cohort 4: Newly Diagnosed …Cohort 5: Primary Central …Cohort 7: Meeting Cohort 1…
NeutropeniaBlood and lymphatic system disorders
AnaemiaBlood and lymphatic system disorders
PyrexiaGeneral disorders
ThrombocytopeniaBlood and lymphatic system disorders
Cytokine release syndromeImmune system disorders
LeukopeniaBlood and lymphatic system disorders
LymphopeniaBlood and lymphatic system disorders
ConstipationGastrointestinal disorders
DiarrhoeaGastrointestinal disorders
HeadacheNervous system disorders
NauseaGastrointestinal disorders
HypogammaglobulinaemiaImmune system disorders
HypokalaemiaMetabolism and nutrition disorders
HypomagnesaemiaMetabolism and nutrition disorders
Febrile neutropeniaBlood and lymphatic system disorders
Abdominal painGastrointestinal disorders
Oedema peripheralGeneral disorders
HypofibrinogenaemiaBlood and lymphatic system disorders
FatigueGeneral disorders
PneumoniaInfections and infestations
Bone painMusculoskeletal and connective tissue disorders
Pain in extremityMusculoskeletal and connective tissue disorders
CoughRespiratory, thoracic and mediastinal disorders
VomitingGastrointestinal disorders
AstheniaGeneral disorders
Escherichia urinary tract infectionInfections and infestations
Aspartate aminotransferase increasedInvestigations
HypophosphataemiaMetabolism and nutrition disorders
PruritusSkin and subcutaneous tissue disorders
HypertensionVascular disorders
Catheter site related reactionGeneral disorders
Urinary tract infectionInfections and infestations
Allergic transfusion reactionInjury, poisoning and procedural complications
Alanine aminotransferase increasedInvestigations
Blood fibrinogen decreasedInvestigations
Decreased appetiteMetabolism and nutrition disorders
Back painMusculoskeletal and connective tissue disorders
Neck painMusculoskeletal and connective tissue disorders
Confusional statePsychiatric disorders
HiccupsRespiratory, thoracic and mediastinal disorders

Most-reported serious reactions: Cytokine release syndrome, Tremor, Confusional state, Febrile neutropenia, Aphasia, Abdominal pain, Haemophagocytic lymphohistiocytosis, Candida sepsis.

Data from ClinicalTrials.gov NCT03484702 adverse events section.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany.
    Albinger N, Hartmann J, Ullrich E. · · 2021 · cited 171× · PMID 33753909 · DOI 10.1038/s41434-021-00246-w
  2. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
    Westin JR, Kersten MJ, Salles G, Abramson JS, et al · · 2021 · cited 163× · PMID 34310745 · DOI 10.1002/ajh.26301
  3. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.
    Wang Y, Tschautscher MA, Rabe KG, Call TG, et al · · 2020 · cited 96× · PMID 31197071 · DOI 10.3324/haematol.2019.224121
  4. CAR-T cell therapy for cancer: current challenges and future directions.
    Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, et al · · 2025 · cited 81× · PMID 40610404 · DOI 10.1038/s41392-025-02269-w
  5. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.
    Chakraborty R, Sidana S, Shah GL, Scordo M, et al · · 2019 · cited 66× · PMID 30500439 · DOI 10.1016/j.bbmt.2018.11.025
  6. Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control.
    Lu L, Xie M, Yang B, Zhao WB, et al · · 2024 · cited 52× · PMID 38394207 · DOI 10.1126/sciadv.adj6251
  7. Prevention and management of secondary central nervous system lymphoma.
    Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K. · · 2023 · cited 47× · PMID 36384246 · DOI 10.3324/haematol.2022.281457
  8. CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?
    Velasco R, Mussetti A, Villagrán-García M, Sureda A. · · 2023 · cited 39× · PMID 37090983 · DOI 10.3389/fneur.2023.1144414

Verify or expand the search:

Other trials of JCAR017

Trials testing the same drug.

Other recruiting trials for Lymphoma, Non-Hodgkin

Currently open trials in the same condition.

Other Celgene trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03484702.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing